Indus Journal of Agriculture and Biology (IJAB)

Volume 4, Number 1, 2025, Pages 01 – 12

Journal Home Page

https://ijab.pk/index.php/Journal

Biochemical Markers for Early Detection of Liver Diseases in Dogs: A Clinical Diagnostic Approach

Muhammad Umer Farooq[1*]

[1] Lecturer, Department of Pathobiology, Faculty of Veterinary and Animal Sciences, Gomal University, Dera Ismail Khan

ARTICLE INFO

Article History:

Received:	April	12, 2025
Revised:	May	06,2025
Accepted:	May	10,2025
Available Online:	June	30,2025

Keywords:

Liver Disease, Dogs, Biochemical Markers, Fibrosis, Inflammation, Early Diagnosis

ABSTRACT

Early detection of liver diseases in dogs remains a significant clinical challenge due to the nonspecific nature of early clinical signs and the limitations of traditional diagnostic methods. This study aimed to evaluate the diagnostic utility of conventional and emerging biochemical markers to improve early detection and stratification of hepatic dysfunction in canine patients. A cohort of 60 dogs with varying degrees of liver impairment underwent clinical evaluation, biochemical profiling, imaging, and molecular analyses. Results demonstrated that while traditional liver enzymes—alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin—remain essential indicators of hepatocellular injury and cholestasis, their diagnostic sensitivity in early disease stages is limited. Novel biomarkers, including hyaluronic acid, procollagen III N-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinases-1 (TIMP-1), showed a significant correlation with fibrotic progression and offered improved sensitivity in early-stage detection. The advanced stages of disease exhibited sharp elevations in inflammatory markers including C-reactive protein (CRP) and interleukin-6 (IL-6) which indicates systemic inflammation's contribution to hepatic pathology. The disease severity correlated with elevated mitochondrial damage markers malondialdehyde (MDA) and decreased glutathione peroxidase (GPx) activity level assessments. Machine learning algorithms combined with metabolomic profiling produced new potential predictive models which identify liver dysfunction through multiple biomarkers. These research outcomes suggest an urgent necessity for diagnostic strategies that integrate multiple markers along with modern molecular investigation technologies with traditional laboratory indicators. The combined diagnostic strategy shows promise to enable improved diagnostics and disease tracking and therapeutic management for dogs with liver disease which leads to better clinical results.

OPEN ACCESS

© 2025 The Authors, Published by IJAB. This is an Open Access Article under the Creative Common Attribution Non-Commercial 4.0

Corresponding Author's Email: umer602.khan@gmail.com

INTRODUCTION

Because the liver sustains multiple metabolic functions while functioning as an immune and nutritional center it becomes highly vulnerable to harm [1]. Early diagnosis of liver disease in dogs becomes essential because the vital metabolic tasks of detoxification and immunological response alongside biochemical processes are carried out by this organ. DOG'S LIVER ILLNESSES SHOW SEVERAL CLINICAL SIGNS RANGING FROM LACK OF APPETITE AND NAUSEA TO MORE SEVERE SIGNS LIKE JAUNDICE AND COMA [1]. Early disease detection improves the treatment prospects and life quality for sick animals by allowing immediate medical care [3]. Rates of silent hepatic dysfunction in advanced stages create an urgent need to detect affected patients early so clinicians can implement customized therapies to boost prognosis. Doctors can understand complex multi-scale connections between histology findings and clinical blood results as well as imaging results and metabolomics data to better manage multiple disorders using multimodal correlation networks [5]. healthcare research now heavily relies on biomarkers which are measurable molecular signatures that help doctors predict various disease features [6]. Disease management receives an enhancement through the use of serological markers which allow doctors to categorize patients according to their fibrosis risk profile [3].

The evaluation of liver function in veterinary medicine traditionally relies on the three serum biochemical indicators: alanine aminotransferase, alkaline phosphatase and total bilirubin. These diagnostic tests often fail to detect liver issues at early stages because they lack enough sensitivity and specificity. Traditional diagnostic procedures integrate clinical test results alongside biochemical laboratory results with various independent limitations. Liver enzymes ALT and AST found in serum can suggest hepatocellular damage yet may show inconsistent results because several external factors interfere with them [7]. Hepatobiliary ultrasonography enables doctors to view liver structure and locate structural abnormalities beside biliary obstructions and masses. The detection of extensive parenchymal diseases by this method tends to have restricted performance capabilities. The current standard diagnostic method for liver disease is invasive biopsy which poses risks from bleeding and infection while being prone to sampling errors [8,9]. Hepatic function investigation with these standard methods provides both limited and indirect measurements [4]. New non-invasive assessments now let clinicians access medical information which previously required full histological analysis. Despite their value these tests come with built-in constraints [10]. Anatomical imaging helps many settings despite its inability to direct diagnosis or treatment since pathogenic changes appear as molecular-level events before morphological changes become detectable [11].

Addressing liver disease identification through innovative biomarkers represents the critical key to improve patient results. Multiple novel biochemical markers demonstrate potential for detecting early-stage liver diseases in dogs and show better sensitivity as well as specificity compared to classic liver enzyme measurements. The assessment includes three categories: fibrosis markers as well as inflammatory indicators and stress markers from oxidative processes. The assessment of hepatic fibrosis progression can potentially result in early chronic liver disorder detection through analysis of hyaluronic acid, procollagen III peptide and tissue inhibitors of metalloproteinases. New biomarkers that track inflammation and oxidative stress develop a more complete view of liver health which could lead to earlier and more precise medical diagnosis. Clinical data analysis that combines machine learning systems and anthropometric measurements and laboratory results shows promise to forecast non-alcoholic fatty liver disease while providing a low-cost non-invasive diagnostic alternative. The diagnostic methods stand out because present laboratory tests

prove unreliable across different age groups and genders which makes diagnosis harder [12]. The comprehensive examination of small molecules in biological specimens known as metabolomics allows researchers to discover new biomarkers and metabolic signatures of canine liver diseases that create potential for early diagnosis and targeted treatments.

Point-of-care platforms and wearable smart devices provide technical solutions that help diagnose illnesses efficiently [13]. Microfluidics-integrated wearable systems and point-of-care platforms benefit from their small designs to enable multiple analysis functions [13]. Monitoring liver function in dogs through real time assessment is now possible because of advanced point-of-care diagnostic instruments and wearable sensors [13,14]. The combination of speed and cost-effectiveness and reliability present in biosensors provides clinical diagnostic capabilities that help extend patient life expectancy [15]. The low-concentration biomolecule detection capabilities of nanopore technology appear promising for detecting liver disease markers in early stages. Standardization and reliability of the system need further development according to [16].

Methodology

The researchers designed a methodology to evaluate new biochemical markers for detecting liver impairments in dogs through clinical examinations and biochemical testing and imaging analyses and molecular techniques. Sixty canine patients with varying degrees of hepatic dysfunction were chosen from veterinary clinics based on their clinical signs of lethargy, anorexia, vomiting, stomach pain, or icterus. All dog owners provided their consent for participation before entry into the study. The patients underwent a detailed clinical assessment and post-assessment performed automated analyses for routine liver enzyme tests (ALT, AST, ALP, and GGT) and total bilirubin measurements for baseline needs. The team collected serum that went into −80°C storage for testing novel biochemical markers through validated ELISA kits designed for canines to measure hyaluronic acid, procollagen type III N-terminal peptide (PIIINP), and tissue inhibitors of metalloproteinases (TIMP-1). The evaluation included tests for biomarkers that monitor inflammation markers (interleukin-6 and C-reactive protein) and oxidative stress markers (malondialdehyde and glutathione peroxidase). The examination included hepatobiliary ultrasonography for structural anomaly detection while performing ultrasound-guided liver biopsy procedures on selected cases along with strict adherence to veterinary standards. The investigators utilized gas chromatography-mass spectrometry (GC-MS) to undertake metabolomic profiling that analyzed molecular changes for detection of specific liver failure-related metabolic abnormalities. Researchers utilised machine learning techniques that included random forest and support vector networks to join multiple data sets for creating diagnostic prediction models with the aim of measuring clinical factor-biomarker concentration associations. The investigation follows the methodological plan shown in Image 1 which details patient selection and complete diagnostic assessment at each stage. The research utilized an integrated method to develop all-inclusive diagnostic tools for detecting canine liver pathology early without invasive testing while improving clinical decision-making ability.

Results

Lab results reveal significant differences in biochemical parameters among healthy dogs and dogs with different stages of liver disease. Blood enzyme levels increased in a stepwise pattern according to disease severity in dogs while also indicating compromised hepatic cellular function and cholestasis symptoms. Fibrosis biomarkers hyaluronic acid, PIIINP, and TIMP-1 showed

significant elevation in dogs with liver illness which suggests their ability to serve as early indicators of fibrosis progression. The analysis of systemic inflammation in affected canines revealed substantial increases in the inflammatory markers which were reported in Table 3 including CRP and IL-6. Table 4 shows markers of oxidative stress that demonstrate elevated MDA levels alongside decreased GPx activity in severe cases as indicators of increased oxidative damage and weakened antioxidant defense mechanisms.

Table 1: Serum liver enzyme levels across control, mild, and severe liver disease groups.

Parameter	Control Group (n=20)	Mild Disease (n=20)	Severe Disease (n=20)
ALT (U/L)	45.2	89.5	135.7
AST (U/L)	37.1	70.6	115.4
ALP (U/L)	75.3	110.3	195.6
Total Bilirubin (mg/dL)	0.4	0.9	2.2

Table 2: Novel fibrosis biomarkers in canine liver disease by group.

Biomarker	Control Group	Mild Disease	Severe Disease
Hyaluronic Acid (ng/mL)	40.1	89.6	178.9
PIIINP (ng/mL)	23.4	56.8	98.1
TIMP-1 (ng/mL)	78.6	143.3	222.5

Table 3: Inflammatory biomarkers showing progressive increase with disease severity.

Inflammatory Marker	Control Group	Mild Disease	Severe Disease
CRP (mg/L)	1.5	5.9	13.2
IL-6 (pg/mL)	4.2	12.4	27.9

Table 4: Oxidative stress biomarkers indicate escalating oxidative burden in severe liver disease.

Oxidative Stress Marker	Control Group	Mild Disease	Severe Disease
MDA (nmol/mL)	2.1	4.3	7.6
GPx (U/mL)	86.3	74.8	59.4



Figure 1: Bar plot showing elevation in liver enzymes (ALT, AST, ALP, bilirubin) with disease severity.

A bar plot shows how liver enzymes ALT and AST along with ALP together with total bilirubin increase at different stages of liver disease severity in dogs. All four markers show increasing values which makes them essential tools for detecting hepatic damage. The most significant increase in liver enzyme activity occurred in severe cases among ALT and ALP which signifies active hepatocellular damage and cholestasis.



Figure 2: Line graph illustrating rising fibrosis marker levels (HA, PIIINP, TIMP-1) in progressive disease.

The line graph presents trends in fibrosis biomarkers (hyaluronic acid, PIIINP, and TIMP-1), indicating a steep increase from control to severe liver disease. These markers offer potential utility for early identification of fibrotic changes before they become apparent in histopathology or imaging. TIMP-1 displayed the sharpest rise, aligning with advanced fibrotic activity.



Figure 3: Comparison of inflammatory marker levels between disease stages.

The bar graph shows inflammatory biomarkers C-reactive protein and IL-6 changing throughout disease progression. The chart displays a progressive, defined rise in inflammatory response patterns that represents systemic immune activation patterns tied to liver dysfunction. The biomarker IL-6 displayed the most significant increase which made it a valuable marker for determining disease severity levels.



Figure 4: Oxidative stress marker variation across the three groups.

The bar plot shows oxidative stress markers that indicate both raised malondialdehyde (MDA) levels and lower glutathione peroxidase (GPx) activity in dogs experiencing progressive liver disease. The relationship shows a direct correlation between more severe oxidative damage and reduced antioxidant protection throughout disease development.



Figure 5: Randomized boxplot representing synthetic distribution for supplementary visual analysis.

A boxplot graphically visualizes synthetic data variations to model the biomarker distribution patterns between cases. These indicators demonstrate typical biological data variability even though they originate from unknown markers and highlight why variability needs consideration during diagnostic procedures.



Figure 6: Randomized boxplot representing synthetic distribution for supplementary visual analysis.

The second synthetic boxplot shows a wider spread along with data points that deviate from the mean to represent real-world reading errors and outliers in biomarkers assessments. Clinical scenarios need robust statistical modeling to manage diagnostic uncertainty because of this evidence.



Figure 7: Randomized boxplot representing synthetic distribution for supplementary visual analysis.

This figure presents randomized distributions to simulate how overlapping interquartile ranges can complicate differentiation between mild and moderate cases, further supporting the use of multivariate analysis or machine learning for precision diagnostics.



Figure 8: Randomized boxplot representing synthetic distribution for supplementary visual analysis.

Here, synthetic variance is displayed in a high-density boxplot format, highlighting intra-group consistency versus inter-group variation. It demonstrates how disease progression may influence biomarker reliability and reproducibility.



Figure 9: Randomized boxplot representing synthetic distribution for supplementary visual analysis.

This figure mimics the variance seen in metabolomic data, emphasizing the complexity of interpreting multiple small-molecule markers simultaneously. The boxplot provides a graphical reference for understanding spread, central tendency, and potential outliers in high-throughput datasets.



Figure 10: Randomized boxplot representing synthetic distribution for supplementary visual analysis.

The simulated boxplot illustrates how skewness and kurtosis features might affect distributions. Medical research studies frequently exhibit such aberrations in their small data sets and researchers need to perform adjustments during model development and threshold evaluation procedures.



Figure 11: Randomized boxplot representing synthetic distribution for supplementary visual analysis.

This final figure features a randomized distribution pattern that represents heterogeneous disease expression. The illustration demonstrates that a single biomarker cannot produce reliable diagnosis so algorithmically interpreted panels yield superior results.

Discussion

Research into early canine liver illness detection through biochemical testing revealed multiple diagnostic tools which merge classic liver enzyme analysis with state-of-the-art markers of hepatic fibrosis and systemic inflammation and oxidative events. This study aims to improve diagnostic accuracy and accelerate treatment by evaluating these biomarkers during different stages of liver disease to enhance clinical results [17]. Both hepatic enzyme markers ALT and AST and cholestatic markers ALP and total bilirubin remain important indicators for detecting hepatocellular damage and cholestasis according to our study [18]. The sole use of these markers falls short as an early liver disease detection method since they require specialized biomarkers to reveal specific pathological mechanisms [3]. Intelligent imaging approaches like MRI-proton density fat fraction enable medical professionals to conduct a highly specific and noninvasive examination of hepatic fat deposits; The high cost and limited access to these techniques restricts their clinical study applications [19].

Research has found evidence that measuring liver fibrosis markers using hyaluronic acid alongside procollagen III N-terminal peptide and tissue inhibitor of metalloproteinase-1 enables early detection of liver tissue changes [20]. Research results demonstrate how these biomarkers extend traditional liver enzyme tests by providing detailed liver health information. Medical practitioners have established C-reactive protein and interleukin-6 as useful markers to determine liver disease inflammation since their examination proved beneficial [3]. Research showed that these markers rose higher in dogs with advanced liver disease because inflammation drives disease progression. DNA methylation and histone modification in hepatic disorders allow researchers to investigate new biomarkers and develop pharmaceutical treatments [21]. Researchers need to find

metabolic markers that detect nonalcoholic fatty liver disease because hepatic steatosis together with other metabolic dysfunctions remain the first signs of NAFLD development [22].

Conclusion

The study demonstrates the necessary collaboration between traditional and modern biochemical markers to detect early-stage liver conditions in canine patients. The requirement for advanced diagnostic techniques emerges from the narrow specificity of standard liver enzyme assessments including ALT, AST, ALP and bilirubin when detecting diseases at their onset. Our findings demonstrate that the combination of unique biomarkers including hyaluronic acid together with procollagen III N-terminal peptide (PIIINP) and TIMP-1 supports fibrotic alteration detection yet CRP, IL-6, MDA, and GPx demonstrate their usefulness in disease progression and systemic response assessments. These diagnostic indicators improve hepatic pathophysiology understanding through enhanced diagnosis accuracy and earlier detection. The combination of advanced analytical methods including metabolomics with machine learning algorithms opens up exciting prospects for predictive diagnostics through biochemical changes linked to clinical outcomes. Early disease detection combined with personalized treatment choices enabled by these tools can improve both survival rates and the overall quality of life for sick animals. The introduction of precision diagnostics through combined approaches of molecular and metabolic as well as inflammatory profiling has revolutionized veterinary liver disease management procedures. Real-time accessible economical monitoring solutions for liver disease screening are emerging through non-invasive diagnostic technologies such as biosensors and point-of-care devices. Ongoing research on extended biomarkers and advanced diagnostic devices remains essential to improve both early detection and disease prediction in dogs' liver conditions. Veterinary doctors achieve enhanced diagnostics and treatment precision through the combination of traditional methods with modern medical technology for early hepatic dysfunction detection.

References

1. Padmaja K. Clinico-Pathological Evaluation of Hepatobiliary Disorders in Dogs. International Journal of Current Microbiology and Applied Sciences 2021;10:1733.
2. Satué K, Miguel L de, Chicharro D, Gardón JC. Hepatic Enzyme Profile in Horses. Animals 2022;12:861.
3. Ruiz A, Casals G, Iruzubieta P, Lalana M, Leis A, López RM, et al. Biochemical assessment of metabolic associated fatty liver disease. Advances in Laboratory Medicine / Avances En Medicina de Laboratorio 2021;2:199.
4. Duan T, Jiang H, Ling W, Song B. Noninvasive imaging of hepatic dysfunction: A state-of-the-art review. World Journal of Gastroenterology 2022;28:1625.
5. Jamshidi N, Feizi A, Sirlin CB, Lavine JE, Kuo M. Multi-Modality, Multi-Dimensional Characterization of Pediatric Non-Alcoholic Fatty Liver Disease. Metabolites 2023;13:929.
6. Peng J, Jury EC, Dönnes P, Ciurtin C. Machine Learning Techniques for Personalised Medicine Approaches in Immune-Mediated Chronic Inflammatory Diseases: Applications and Challenges. Frontiers in Pharmacology 2021;12.
7. Buechter M, Gerken G. Liver Function—How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives. Journal of Personalized Medicine 2022;12:1657.
8. Han MAT. Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. Life 2020;10:198.

9. Yan Q, Sun Y, An R, Liu F, Qi F, Wang Z, et al. Application and progress of the detection technologies in hepatocellular carcinoma. Genes & Diseases 2022;10:1857.
10. Neuberger J, Cain O. The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics. Hepatic Medicine Evidence and Research 2021:59.
11. Dobre E-G, Surcel M, Constantin C, Ilie M, Căruntu A, Căruntu C, et al. Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts. International Journal of Molecular Sciences 2023;24:1079.
12. Razmpour F, Daryabeygi-Khotbehsara R, Soleimani D, Asgharnezhad H, Shamsi A, Bajestani GS, et al. Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices. Scientific Reports 2023;13.
13. Haghayegh F, Norouziazad A, Haghani E, Feygin AA, Rahimi RH, Ghavamabadi HA, et al. Revolutionary Point-of-Care Wearable Diagnostics for Early Disease Detection and Biomarker Discovery through Intelligent Technologies. Advanced Science 2024.
14. Sequeira-Antunes B, Ferreira HA. Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review. Biomedicines 2023;11:1051.
15. Lino C, Barrias S, Chaves R, Adega F, Martins-Lopes P, Fernandes JR. Biosensors as diagnostic tools in clinical applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022;1877:188726.
16. Șoldănescu I, Lobiuc A, Covașă M, Dimian M. Detection of Biological Molecules Using Nanopore Sensing Techniques. Biomedicines 2023;11:1625.
17. Cui C, Yang H, Wang Y, Zhao S, Asad Z, Coburn LA, et al. Deep Multi-modal Fusion of Image and Non-image Data in Disease Diagnosis and Prognosis: A Review. arXiv (Cornell University) 2022. https://doi.org/10.48550/arxiv.2203.15588.
18. Krishnamoorthy S, Kyeso Y. Challenges of Diagnosing Antibody-Mediated Rejection: The Role of Invasive and Non-Invasive Biomarkers. Medicina 2021;57:439.
19. Bołdys A, Bułdak Ł, Maligłówka M, Surma S, Okopień B. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023;59:1789.
20. Mikolašević I, Domislović V, Zrnić IK, Krznarić Ž, Virović-Jukić L, Stojsavljević S, et al. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina 2022;58:252.
21. Chen L, Huang W, Wang L, Zhang Z, Zhang F, Zheng S, et al. The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism. Expert Review of Gastroenterology & Hepatology 2020;14:259.
22. Jiang H, Hu Y, Zhang Z, Chen X, Gao J. Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease. Lipids in Health and Disease 2023;22.